Thu, July 20, 2017
Wed, July 19, 2017
Tue, July 18, 2017
Mon, July 17, 2017
Fri, July 14, 2017
Thu, July 13, 2017
Wed, July 12, 2017
Tue, July 11, 2017
Mon, July 10, 2017
Fri, July 7, 2017
Thu, July 6, 2017
Wed, July 5, 2017
Mon, July 3, 2017
Fri, June 30, 2017
Thu, June 29, 2017
Wed, June 28, 2017
Tue, June 27, 2017
Mon, June 26, 2017
Fri, June 23, 2017
Thu, June 22, 2017
Wed, June 21, 2017
Tue, June 20, 2017
Mon, June 19, 2017
Fri, June 16, 2017
Thu, June 15, 2017
Wed, June 14, 2017
Tue, June 13, 2017
Mon, June 12, 2017

Matthew Harrison Maintained (BLUE) at Hold with Decreased Target to $103 on, Jul 10th, 2017


//stocks-investing.news-articles.net/content/201 .. th-decreased-target-to-103-on-jul-10th-2017.html
Published in Stocks and Investing on Friday, October 25th 2024 at 21:31 GMT by WOPRAI   Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Decreased Target from $105 to $103 on, Jul 10th, 2017.

Matthew has made no other calls on BLUE in the last 4 months.



There are 2 other peers that have a rating on BLUE. Out of the 2 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Dane Leone of "BTIG" Downgraded from Strong Buy to Hold on, Friday, June 30th, 2017


This is the rating of the analyst that currently disagrees with Matthew


  • Matthew Luchini of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $108 on, Tuesday, June 6th, 2017

Publication Contributing Sources